{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:31:51Z","timestamp":1793712711610,"version":"4.6.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007174","name":"Pfizer Inc Boulder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007174","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jaci.2021.10.036","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T11:13:46Z","timestamp":1638357226000},"page":"1318-1328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9363-324X","authenticated-orcid":false,"given":"Emma","family":"Guttman-Yassky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisleen","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeriel","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Banfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Ann","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Dowty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.10.036_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2016.10.004","article-title":"Alopecia areata: what\u2019s new in epidemiology, pathogenesis, diagnosis, and therapeutic options?","volume":"86","author":"Dainichi","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2021.10.036_bib3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000497166","article-title":"Psychological profile and quality of life of patients with alopecia areata","volume":"5","author":"Velez-Muniz","year":"2019","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.jaci.2021.10.036_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijwd.2017.07.001","article-title":"Quality of life in mild and severe alopecia areata patients","volume":"4","author":"Abedini","year":"2018","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib5","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","article-title":"The changing landscape of alopecia areata: the therapeutic paradigm","volume":"34","author":"Renert-Yuval","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaci.2021.10.036_bib6","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.10.036_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jaci.2021.10.036_bib8","first-page":"47","article-title":"Excellent response to tofacitinib treatment in a patient with alopecia universalis","volume":"26","author":"Erduran","year":"2017","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.jaci.2021.10.036_bib9","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1002\/ccr3.2484","article-title":"An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: a case report and a review of the literature","volume":"7","author":"Berbert Ferreira","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jaci.2021.10.036_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib12","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jaad.2019.08.080","article-title":"Combination tofacitinib and oral minoxidil treatment for severe alopecia areata","volume":"85","author":"Wambier","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib13","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jaad.2017.06.027","article-title":"Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series","volume":"77","author":"Park","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13118","article-title":"Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata","volume":"32","author":"Akdogan","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaci.2021.10.036_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/ijt.ijt_21_18","article-title":"Tofacitinib (selective Janus kinase inhibitor 1 and 3): a promising therapy for the treatment of alopecia areata: a case report of six patients","volume":"10","author":"Shivanna","year":"2018","journal-title":"Int J Trichology"},{"key":"10.1016\/j.jaci.2021.10.036_bib16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study","volume":"235","author":"Almutairi","year":"2019","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2021.10.036_bib17","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/exd.13060","article-title":"Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers","volume":"25","author":"Jabbari","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2021.10.036_bib20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000479722","article-title":"Complete regrowth of beard hair with ruxolitinib in an alopecia universalis patient","volume":"4","author":"Ramot","year":"2018","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.jaci.2021.10.036_bib21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jdcr.2019.07.005","article-title":"Treatment of severe alopecia areata with baricitinib","volume":"5","author":"Olamiju","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaci.2021.10.036_bib22","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.10.036_bib23","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2021.10.036_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121949","article-title":"High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata","volume":"3","author":"de Jong","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2021.10.036_bib25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/1346-8138.14986","article-title":"Janus kinase inhibitors: an innovative treatment for alopecia areata","volume":"46","author":"Park","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib26","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3389\/fimmu.2019.01862","article-title":"Tyrosine kinases in autoimmune and inflammatory skin diseases","volume":"10","author":"Szilveszter","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2021.10.036_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jocd.12970","article-title":"The profile of cytokines (IL-2, IFN-gamma, IL-4, IL-10, IL-17A, and IL-23) in active alopecia areata","volume":"19","author":"Gautam","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijd.IJD_68_18","article-title":"Pathogenesis of alopecia areata based on bioinformatics analysis","volume":"64","author":"Zhang","year":"2019","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib29","first-page":"130","article-title":"Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity","volume":"182","author":"Bain","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jaci.2015.11.001","article-title":"Extensive alopecia areata is reversed by IL-12\/IL-23p40 cytokine antagonism","volume":"137","author":"Guttman-Yassky","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.10.036_bib31","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.jaci.2018.06.029","article-title":"An integrated model of alopecia areata biomarkers highlights both TH1 and TH2 upregulation","volume":"142","author":"Song","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.10.036_bib32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating Th2\/Tc2\/Th22, within the skin-homing and systemic T-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.10.036_bib33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/exd.12918","article-title":"Biomarkers of alopecia areata disease activity and response to corticosteroid treatment","volume":"25","author":"Fuentes-Duculan","year":"2016","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib34","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1111\/all.14814","article-title":"An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata","volume":"76","author":"Glickman","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2021.10.036_bib35","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jaci.2021.10.036_bib36","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2021.10.036_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.10.036_bib38","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","article-title":"Oral JAK\/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.10.036_bib39","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.jaci.2018.02.040","article-title":"Early-onset pediatric atopic dermatitis is characterized by TH2\/TH17\/TH22-centered inflammation and lipid alterations","volume":"141","author":"Brunner","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.10.036_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2015.07.023","article-title":"Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis","volume":"242","author":"Lind","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jaci.2021.10.036_bib41","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2020.04.138","article-title":"Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation","volume":"84","author":"Glickman","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1016\/j.jaci.2021.10.036_bib43","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jaci.2018.07.028","article-title":"Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab","volume":"143","author":"Brunner","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.10.036_bib44","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2147\/DDDT.S172638","article-title":"Role of janus kinase inhibitors in the treatment of alopecia areata","volume":"12","author":"Triyangkulsri","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jaci.2021.10.036_bib45","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaci.2019.06.047","article-title":"Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial","volume":"144","author":"Bissonnette","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2021.10.036_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"Hanzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jaci.2021.10.036_bib47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.anai.2018.08.024","article-title":"Atopic dermatitis in African American patients is TH2\/TH22-skewed with TH1\/TH17 attenuation","volume":"122","author":"Sanyal","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2021.10.036_bib48","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1111\/jocd.13966","article-title":"Experience with oral tofacitinib in severe alopecia areata with different clinical responses","volume":"20","author":"Dincer Rota","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.jaci.2021.10.036_bib49","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/eji.201948521","article-title":"Cell\u00a0surface IL-1\u03b1 trafficking is specifically inhibited by interferon-\u03b3, and associates with the membrane via IL-1R2 and GPI anchors","volume":"50","author":"Chan","year":"2020","journal-title":"Eur J Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921018236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921018236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:37:10Z","timestamp":1758793030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921018236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0091674921018236"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.10.036","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.10.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}